Verdence Capital Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
Verdence Capital Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$551,379
+4.5%
14,434
-1.3%
0.06%
-1.6%
Q2 2023$527,488
-4.2%
14,624
+1.4%
0.06%
-9.0%
Q1 2023$550,623
-34.4%
14,418
-2.3%
0.07%
-35.0%
Q4 2022$839,958
+35.5%
14,762
-5.8%
0.10%
+19.8%
Q3 2022$620,000
-9.2%
15,676
+1.0%
0.09%
-2.3%
Q2 2022$683,000
+22.2%
15,528
+10.7%
0.09%
+39.7%
Q1 2022$559,000
+0.9%
14,021
+1.8%
0.06%
-3.1%
Q4 2021$554,000
+18.6%
13,770
+19.9%
0.06%
+6.6%
Q3 2021$467,000
-10.5%
11,488
-0.1%
0.06%
-15.3%
Q2 2021$522,000
+8.5%
11,495
-0.3%
0.07%
-11.1%
Q1 2021$481,000
-2.4%
11,531
-0.2%
0.08%
-12.9%
Q4 2020$493,000
+64.9%
11,551
+1.4%
0.09%
+34.8%
Q3 2020$299,000
-2.0%
11,3880.0%0.07%
-8.0%
Q2 2020$305,000
+48.8%
11,3880.0%0.08%
+23.0%
Q1 2020$205,000
+1.5%
11,3880.0%0.06%
+24.5%
Q4 2019$202,000
+14.1%
11,3880.0%0.05%
-2.0%
Q3 2019$177,000
-9.7%
11,3880.0%0.05%
-10.7%
Q2 2019$196,000
+7.1%
11,3880.0%0.06%
+12.0%
Q1 2019$183,000
+9.6%
11,3880.0%0.05%
+6.4%
Q4 2018$167,000
-19.3%
11,3880.0%0.05%
-7.8%
Q3 2018$207,000
+7.8%
11,3880.0%0.05%
+8.5%
Q2 2018$192,000
-13.9%
11,3880.0%0.05%
-13.0%
Q1 2018$223,000
-3.5%
11,3880.0%0.05%
-1.8%
Q4 2017$231,00011,3880.06%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders